Based on the Adicet Bio Inc stock forecast from 0 analysts, the average analyst target price for Adicet Bio Inc is not available over the next 12 months. Adicet Bio Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Adicet Bio Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Adicet Bio Inc’s stock price was USD 0.54. Adicet Bio Inc’s stock price has changed by -15.92% over the past week, -32.36% over the past month and -75.14% over the last year.
No recent analyst target price found for Adicet Bio Inc
No recent average analyst rating found for Adicet Bio Inc
Company Overview Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts. Read Less
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in ...Read More
Frequently Asked Questions About Adicet Bio Inc (ACET) Stock
Stock Target Advisor's fundamental analysis for Adicet Bio Inc's stock is Bearish.
Unfortunately we do not have enough data on ACET's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ACET's stock to indicate what its average analyst target is.
ACET stock's Price/Earning ratio is 39.60.
Our analysis grades ACET stock's Price / Earning ratio at F. This means that ACET stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ACET may be a overvalued for its sector.
The last closing price of ACET's stock was USD 0.54.
The most recent market capitalization for ACET is USD 0.06B.
Unfortunately we do not have enough analyst data on ACET's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Adicet Bio Inc's stock.
As per our most recent records Adicet Bio Inc has 152 Employees.
Adicet Bio Inc's registered address is 131 Dartmouth Street, Boston, MA, United States, 02116.
You can get more information about it from Adicet Bio Inc's website at https://www.adicetbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Adicet Bio Inc (ACET) Stock
Stock Target Advisor's fundamental analysis for Adicet Bio Inc's stock is Bearish.
Unfortunately we do not have enough data on ACET's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ACET's stock to indicate what its average analyst target is.
ACET stock's Price/Earning ratio is 39.60.
Our analysis grades ACET stock's Price / Earning ratio at F. This means that ACET stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ACET may be a overvalued for its sector.
The last closing price of ACET's stock was USD 0.54.
The most recent market capitalization for ACET is USD 0.06B.
Unfortunately we do not have enough analyst data on ACET's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Adicet Bio Inc's stock.
As per our most recent records Adicet Bio Inc has 152 Employees.
Adicet Bio Inc's registered address is 131 Dartmouth Street, Boston, MA, United States, 02116.
You can get more information about it from Adicet Bio Inc's website at https://www.adicetbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ACET !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
